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Sununary-The excitatory amino acid antagonists o,L-2-amino-5-phosphonovalerate (D,L-APS), its 
isomers D-( -)-AP5 and L-( +)-AP5, o,L-2-amino-4-phosphonobutyrate (AP4), D,L-2-amino-Fphos- 
phonoheptanoate (AP7), /I-o-aspartylaminomethylphosphonic acid (ASP-AMP), cis-2,3-piperidinedi- 
carboxylic acid (cis-PDA), and y-o-glutamylaminomethylsulphonic acid (GAMS) were tested for their 
ability to produce a phencyclidine (PCP)-like catalepsy in pigeons when administered intracerebro- 
ventricularly. Each of the antagonists produced catalepsy, although L-APS, and the non-selective 
antagonists GAMS and cis-PDA, produced the effect only at toxic doses. The rank order of potency 
to produce catalepsy was API > D-AP5 > D,L-APS > cis-PDA > ASP-AMP > AP4 z L-AP5 > GAMS; 
there was a strong positive correlation between this rank order of potency in viuo and the potency order 
of these compounds in vitro as NMDA antagonists. The antagonists did not displace significant amounts 
of [3H]N-[I-(2-thienyl)cyclohexyl]piperidine (a congener of phencyclidine) from its recognition site in the 
brain of pigeon. Thus, the PCP-like catalepsy that is produced by the excitatory neurotransmission at 
NMDA-preferring receptors that are distinct from, but related to, PCP receptors. The results strongly 
support the hypothesis that a reduction of neurotransmission at excitatory synapses, utilizing NMDA- 
preferring receptors, may underlie catalepsy in pigeons induced by PCP. 
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Receptors for excitatory amino acids are classified 
according to their selective sensitivity to activation by 
N-methyl-D-aspartate (NMDA), kainate, or quis- 
qualate (Watkins and Evans, 1981). The NMDA- 
preferring receptor is the most extensively character- 
ized of the three types of receptor, because of the 
availability of potent and highly selective NMDA 
antagonists, such as D,L-2-amino-5-phosphono- 
valerate (D,L-APS). 
Phencyclidine (PCP) and PCP-like drugs selectively 
antagonize excitation of neurons induced by NMDA 
with little effect on the equivalent excitation induced 
by kainate or quisqualate (Anis, Berry, Burton and 
Lodge, 1983). Therefore, certain behavioral effects of 
PCP may be mediated by a reduction of neuro- 
transmission at excitatory synapses utilizing NMDA- 
preferring receptors. If this hypothesis is correct, 
drugs that are known to antagonize the effects of 
NMDA should produce PCP-like behavioral effects. 
Because of its pharmacological specificity and stereo- 
selectivity, the catalepsy test in pigeons provides a 
*Portions of these data were presented by W.K. at the 
meeting of the Federation bf American Societies for 
Experimental Biology, St Louis, MO. (Mudar, Koek, 
Jacobson and Woods, 1986). 
suitable procedure for studying PCP-like behavioral 
activity of compounds (Koek, Woods, Rice, 
Jacobson, Huguenin and Burke, 1984). 
Recently, the selective NMDA antagonist 
D,L-2-amino-5phosphonovalerate (D,L-APS), was 
found to produce PCP-like catalespy in pigeons, 
lending support to this hypothesis of mechanism of 
action for PCP (Koek, Kleer, Mudar and Woods, 
1986a). The aims of the present study were: (1) to 
investigate whether other excitatory amino acid an- 
tagonists produced PCP-like catalepsy in pigeons; (2) 
to investigate whether their ability to induce PCP-like 
catalepsy was positively correlated with their rank 
order of potency as NMDA antagonists; and (3) to 
study whether the excitatory amino acid antagonists 




White Cameaux pigeons were used. They were 
housed individually with food, grit and water freely 
available. 
A chronic, indwelling guide cannula was implanted 
in each pigeon with the tip inserted directly into the 
lateral ventricle; the patency of the cannula was 
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assessed by a radiographic method (France, Adams 
and Woods, 1985) following surgery and once every 
month afterwards. 
Drugs were injected intracerebroventricularly 
(i.c.v.) in a volume of 10 PI/pigeon, during a I-min 
period. The injection cannula was removed from the 
guide cannula 30 set after the end of the injection 
period. The presence or absence of catalespy (defined 
as loss of righting, without head-drop and with- 
out eye closure; Koek et al., 1984; Koek, Woods, 
Jacobson, Rice and Lessor, 1986b) was assessed at 
successive time intervals after the injection. Each dose 
was tested in 556 pigeons that were selected at 
random from the group of cannulated pigeons 
(n =40). Only data obtained from tests that were 
both preceded and followed by a positive X-ray were 
included in the analysis. Tests with drugs were sepa- 
rated by at least 48 hr. 
Binding assay for TCP 
Whole brain (minus cerebellum) from White Car- 
neaux pigeons was removed and frozen immediately. 
Frozen brains was thawed and homogenized in 70 vol 
of 5 mM Tris-HCl buffer (pH 7.4) with a Brinkman 
polytron (setting 6, 20 set). The homogenates were 
centrifuged three times at 20,000 g for 20 min at 5°C 
with intervening resuspensions of the pellet in fresh 
buffer. The final pellet was resuspended in 70 vol of 
fresh Tris buffer and stored at 0°C. 
Binding of [3H]N-l[l-(2-thienyl)cyclohexyl]piper- 
idine (TCP) to membranes from brain was deter- 
mined by incubating 900~1 of tissue (containing 
0.5mg of protein), 50~1 of 5pM [3H]TCP 
(55.3 Ci/mmol; New England Nuclear) and 50 ~1 
buffer (or a final concentration of 10 PM TCP for a 
determination of nonspecific binding) for 1 hr at 5°C. 
The reaction was terminated by rapid filtration 
(Brandel Cell Harvester, Gaithersburg, Maryland) 
through Schleicher & Schuell No. 32 filters which 
had been presoaked in 0.03% polylysine (Sigma, 
M, 150,00(r300,000) for 2 hr at 5°C. The filters 
were washed with two 5.0 ml aliquots of ice-cold 
Tris buffer and placed in counting vials containing 
10 ml of Hydrofluor scintillation cocktail (National 
Diagnostics). 
The AP4, D,L-AP5, AP7, GAMS, and cis-PDA, in 
concentrations of 1, 10 and lOOnM, and 1, 10, and 
100 PM, were examined for their ability to inhibit the 
binding of [3H]TCP to recognition sites in the mem- 
branes from the brain of pigeons. 
Drugs 
The following drugs were used: D,L-2- 
amino-5-phosphovalerate (D,L-AP5), isomers D-( -)- 
AP5 and L-( +)-AP5, D,L-2-amino-4-phosphono- 
butyrate (AP4), D,L-2-amino7-phosphonoheptanoate 
(AP7), b-D-aspartylaminomethylphosphonic acid 
(ASP-AMP), cis-2,3-piperidinedicarboxylic acid (cis- 
PDA) and y -D-ghrtamylaminomethylsulphonic acid 
(GAMS). Each was dissolved in 1.0 N NaOH, to 
which sterile water was added: pH 6-8. Each of 
the above was purchased from Tocris Chemicals 
(Buckhurst Hill, England), except for TCP and 




Each of the excitatory amino acid antagonists 
induced PCP-like catalepsy in pigeons at 15 min after 
intracerebroventricular administration (Fig. 1). For 
all drugs, except L-AP5, the straight lines shown in 
Figure 1 provided a sufficient fit (Chi-square test; 
P > 0.05) to the data. Further, these lines did not 
deviate significantly from parallel (slope-ratio test; 
P > 0.05). The D-(-)-AP5 was about 24 times more 
potent than L-( +)-AP5 in producing catalepsy (ED,,: 
0.21 and 5pmol, respectively) and was nearly equi- 
potent to the racemate, D,L-AP5 (ED,,: 0.22,umol). 
Unlike the racemate or the D-isomer of AP5, 
L-( +)-AP5 (top panel, Fig. 1) failed to induce cata- 
lepsy in all pigeons at the lowest dose tested (i.e. 
5.6pmol; a dose that was lethal in 40% of the 
pigeons). As a result, the ED,, dose of L-(+)-AP5 
could not be calculated by means of the method of 
Litchfield and Wilcoxon (1949) but was calculated 
by interpolation. 
The congeners of D,L-AP5, AP4 and AP7, also 
induced catalepsy, as did the dipeptide ASP-AMP 
(Fig. 1, middle panel); the potency order of 
these compounds to induce catalespy was 
AP7 > AP5 > ASP-AMP > AP4. In addition, cata- 
lepsy was induced by intracerebroventricuiar admini- 
stration of the non-selective antagonists cis-PDA and 
GAMS. However, this effect was produced only at 
lethal doses; 1 .O pmol of cis-PDA was lethal in 40% 
of the animals tested, as was 18.0 pmol of GAMS. 
Compared to D,L-APS, the potency order of these 
compounds to induce catalespy was 
D,L-AP5 > cis-PDA > GAMS (Fig. 1, lower panel). 
The mean duration of catalepsy that was induced 
by the excitatory amino acid antagonists at the 
largest doses was not significantly different 
(F[6,27] = 1.19. P > 0.2; one-way analysis of vari- 
ance, Keppel, 1973). The mean duration of catalepsy 
(+ 1 SEM), averaged for the drugs, was 
79.4 f 12.9 min. 
Table 1 shows the ED,, values of the excitatory 
amino acid antagonists to produce PCP-like cata- 
lepsy. A statistically significant and positive cor- 
relation of 0.81 (Spearman rank correlation 
coefficient; Siegel, 1956) was found between the order 
of potency of the antagonists to produce catalepsy 
and their order of potency in blocking the excitatory 
effects of NMDA on motor neurons of the frog. 
Further, a significant positive correlation of 0.79 was 
found between the order of potency of the antago- 
nists to produce PCP-like catalepsy and the order of 
potency of these compounds to inhibit the binding of 
[‘HID-AP5 in brain of the rat. Finally, the order of 
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Fig. 1. Catalepsy in pigeons, assessed for 15 min after intracerebroventricular administration of excitatory 
amino acid antagonists (upper panel: the selective NMDA antagonist AP5 and its isomers; middle panel: 
congeners of AP5 and the selective NMDA antagonist ASP-AMP, lower panel: the non-selective 
antagonists cis-PDA and GAMS; for purposes of comparisons, the same dose-effect curve of D,L-AP~ 
is shown in all three panels). Ordinates: percentage of pigeons showing PCP like catalepsy, plotted on 
a probit scale. Abscissae: dose administered intracerebroventricularly in pmol/pigeon. 0 D-(-)-AP5; l 
D,L-AP5; IJ L-( +)-AP5. 
N.P. 26/+B 
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Table 1, Correlations between the rank order of excitatory amino acid antagonists to produce PCP-like catalepsy 
in pigeons and their potency order to inhibit effects of NMDA, kainate and quisqualate on motor neurons of the 
frog (from Jones et al., 1984) and to inhibit binding of [)H]D-APS in the brain of the rat (from Olverman ef al., 1984). 
Correlations were measured by means of Spearman’s rank correlation coefficient r,; a two-tailed test was used to 
assess statistical sianificance 
Relative potency in blocking 
PCP-like effects excitatory amino acids 
catalepsy on motor neurons of the frogs Relative potency 
in pigeons ID-( -)-AP5 at NMDA site = 1 .O] m inhibiting binding of 
(ED,, in - --- ---.-- (‘H]o,t-AP5 in brain of 
pmol) NMDA K&ate Quisqualate the rat [D-( -)-AP5 = 1 S] 
w-API 0.032 0.61 0.0007 I 0.0014 0.26 
D-AP5 0.21 I.0 0.0022 0.0042 1.0 
D,L-Al’5 0.22 0.52 0.00072 0.0016 0.36 
cis-PDA 0.47 0.022 0.013 0.01 I 0.0079 
ASP-AMP 0.60 0.48 0.0042 0.0073 - 
AP4 4.13 0.001* - 0.0024 
t-APS 5.0 0.032* 0.01 1 
GAMS 6.68 0.0015 0.11 0.014 0.00081 
r* 0.8 1 -0.77 -0.89 0.79 
P< 0.0s NS 0.05 0.05 
*From Evans, Francis, Jones, Smith and Watkins (1982). 
NS-not statistically significant. 
potency of the antagonists to produce catalepsy and 
their order of potency in blocking the effects of 
kainate and of quisqualate on motor neurons of the 
frog were correlated negatively. 
Binding assay for TCP 
In the binding assay, AP4, D,L-APS, API, GAMS, 
and cis-PDA did not displace significant amounts of 
[3H]TCP from its binding sites in membranes from 
the brain of the pigeon, neither when tested in the 
effective concentration range of TCP (E& = 38 nM) 
and PCP (EC,, = 129 nM), nor when tested in the 
micromolar range (data not shown). Even in a con- 
centration of 100 PM, AP4, AP5, API, cis-PDA and 
GAMS displaced less than 50% [3H]TCP. 
DISCUSSION 
Catalepsy in pigeons, an effect that is produced 
exclusively by PCP-like agents (e.g. Koek et al., 
1984), was shown to be also produced by intra- 
cerebroventricular administration of excitatory 
amino acid antagonists (i.e. D,L-AP5, D-(-) and 
L-(+)-APS, AP4, AP7, ASP-AMP, cis-PDA and 
GAMS). 
Likewise, catalepsy is produced by PCP-like 
compounds that stereoselectively displace PCP from 
recognition sites (e.g. Koek et al., 1984). The 
APS-induced catalepsy was stereoselectively pro- 
duced, as shown by the observation that D-( -)-AP5 
was more potent than L-( +)-AP5 in producing cata- 
lepsy. Further, whereas D-( -)-AP5 produced cata- 
lepsy in all the pigeons tested, L-( +)-AP5 failed to do 
so when tested in up to lethal doses. If the ability to 
induce catalepsy in pigeons resides almost exclusively 
in the D-isomer of AP5, it would be expected that 
D-AP5 would be twice as potent as the racemate. The 
absence of a potency difference between D-(-)-AP5 
and D,L-AP5, that was observed in the present study, 
may perhaps be related to a degree of variability in 
the behavioral data that precluded the detection of 
small differences in potency. 
On the basis of the relative potencies of the ex- 
citatory amino acid antagonists in blocking the effects 
of NMDA on motor neurons of the frog (Jones, 
Smith and Watkins. 1984) and in inhibiting the 
binding of the highly selective NMDA antagonist 
[‘HID-(-)-AP5 in brain of the rat (Olverman, Jones 
and Watkins, 1984), a potency order of D-(-)- 
APS > AP7 > D,L - AP5 > ASP - AMP > cis - PDA > 
GAMS > AP4 in producing PCP-like catalepsy can 
be predicted for these compounds if their catalepsy- 
inducing effects are dependent upon antagonism at 
NMDA-preferring receptors. Indeed, the rank order 
of potency of these compounds to produce catalepsy 
was found to be in good agreement with the rank 
order of potency as predicted from electro- 
physiological and binding data; given this strong 
positive correlation, a negative relationship between 
the rank order of potency to induce catalepsy and the 
rank order of potency to antagonize the electro- 
physiological effects of kainate~quisqualate may be 
expected, because the compounds selected for study 
resulted from attempts to develop selective NMDA 
antagonists and selective non-NMDA antagonists. 
The significant correlation between the potencies of 
the excitatory amino acid antagonists to produce 
catalepsy and their potencies as NMDA antagonists 
suggests that the catalepsy produced by these com- 
pounds may result from reduced excitatory neuro- 
transmission at NMDA-preferring receptors. These 
receptors may be distinct from PCP receptors, be- 
cause the antagonists failed to displace significant 
amounts of labelled TCP from binding sites for PCP 
in brain of pigeon (this study) and because the 
congener of PCP ketamine has been reported to be 
inactive at displacing APS (Olverman and Watkins, 
cited in Martin and Lodge, 1985). However, the 
NMDA-preferring receptor and the PCP receptor 
may form a receptor complex similar to that demon- 
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strated for the benzodiazepines and y -aminobutyric 
acid-(GABA) (Loo, Braunwalder, Lehmann and 
Williams, 1986a). Since the experiments described 
here were conducted, Loo, Braunwalder, Lehmann 
and Williams (1986b) reported that the binding of 
[)H]TCP is dependent upon the presence of endo- 
genous glutamate in membrane preparations of the 
rat; as the concentration of endogenous glutamate 
was reduced by repeated washing of the membrane 
preparations, there was a parallel reduction in the 
binding of [3H]TCP. Further, AP7 attenuated stimu- 
lation by glutamate of the binding of TCP. Thus, the 
effects of NMDA antagonists on the binding of TCP 
may be dependent on the concentration of endo- 
genous amino acid receptor agonists; in the present 
study, the concentration of these endogenous ago- 
nists was not controlled. 
The results presented in this study support the 
hypothesis that a reduction of neurotransmission at 
excitatory synapses utilizing NMDA receptors may 
underlie certain behavioral effects of PCP (Koek et 
al., 1986a). 
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